This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
210
Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
Research Site
Chula Vista, California, United States
Research Site
San Diego, California, United States
Examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight in obese subjects.
Time frame: open ended
Examine the long-term safety and tolerability of SC injected pramlintide in obese subjects.
Time frame: open ended
Investigate the long-term effect of SC injected pramlintide in obese subjects on various anthropometric and pharmacodynamic parameters.
Time frame: open ended
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Walnut Creek, California, United States
Research Site
Miami, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Overland Park, Kansas, United States
Research Site
Baton Rouge, Louisiana, United States
Research Site
Detroit, Michigan, United States
...and 11 more locations